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Abstract
Objective HIF-1/HRE pathway is a promising target for
the imaging and the treatment of intractable malignancy
(HIF-1; hypoxia-inducible factor 1, HRE; hypoxia-
responsive element). The purposes of our study are: (1) to
assess the gene activation levels resulting from various
numbers of HREs under various hypoxic conditions, (2) to
evaluate the bidirectional activity of multiple HREs, and
(3) to confirm whether multiple HREs can induce gene
expression in vivo.
Methods Human colon carcinoma HCT116 cells were
transiently transfected by the constructs containing a firefly
luciferase reporter gene and various numbers (2, 4, 6, 8, 10,
and 12) of HREs (nHRE?, nHRE-). The relative lucif-
erase activities were measured under various durations of
hypoxia (6, 12, 18, and 24 h), O2 concentrations (1, 2, 4, 8,
and 16 %), and various concentrations of deferoxamine
mesylate (20, 40, 80, 160, and 320 lg/mL growth med-
ium). The bidirectional gene activation levels by HREs
were examined in the constructs (dual-luc-nHREs) con-
taining firefly and Renilla luciferase reporter genes at each
side of nHREs. Finally, to test whether the construct con-
taining 12HRE and the NIS reporter gene (12HRE-NIS)
can induce gene expression in vivo, SPECT imaging was
performed in a mouse xenograft model.
Results (1) gene activation levels by HREs tended to
increase with increasing HRE copy number, but a satura-
tion effect was observed in constructs with more than 6 or 8
copies of an HRE, (2) gene activation levels by HREs
increased remarkably during 6–12 h of hypoxia, but not
beyond 12 h, (3) gene activation levels by HREs decreased
with increasing O2 concentrations, but could be detected
even under mild hypoxia at 16 % O2, (4) the bidirectionally
proportional activity of the HRE was confirmed regardless
of the hypoxic severity, and (5) NIS expression driven by
12 tandem copies of an HRE in response to hypoxia could
be visualized on in vivo SPECT imaging.
Conclusion The results of this study will help in the
understanding and assessment of the activity of multiple
HREs under hypoxia and become the basis for hypoxia-
targeted imaging and therapy in the future.
Keywords Hypoxia-responsive element (HRE) 
Reporter genes  Tumor hypoxia  Molecular imaging 
Gene therapy
Introduction
In tumor cells at low oxygen levels, genetic response to
hypoxia is initiated by binding of hypoxia-inducible factor-
1 (HIF-1), which is a major transcriptional activator of
hypoxia-regulated genes, to hypoxia-responsive elements
(HREs), which are transcription enhancers located in the
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promoter regions of hypoxia-regulated genes such as
erythropoietin (Epo) and vascular endothelial growth factor
(VEGF) genes [1, 2]. Tumor cells are thought to acquire
resistance to radiotherapy and chemotherapy as the result
of a cascade of expression of various hypoxia-regulated
genes [3]. Therefore, the HIF-1/HRE system of gene reg-
ulation is a promising target for the imaging and treatment
of intractable malignancy [4, 5].
Multiple copies of HREs have been synthesized and
applied in in vivo experiments for imaging reporter gene
expression in response to hypoxia [6–8] and for hypoxia-
targeted gene therapy [9–11]. The correlation between
hypoxia and gene activation levels by such multiple HREs
has to rely upon in vitro experiments of cell cultures,
because there is no appropriate method to evaluate hypoxia
in essentially inhomogeneous tumor masses. However,
basic reports on the in vitro assessment of gene activation
levels by multiple HREs under various hypoxic conditions
are limited (Table 1) [12–14]. Although the results of these
studies agree that the VEGF HRE has the highest potential
for gene activation, the effect of HRE copy number on
gene activation remains controversial. Shibata et al. [12]
have suggested that the saturated hypoxia responsiveness
of ten copies of an HRE is similar to that of five copies, but
Ruan et al. [13] reported that hypoxic induction of gene
expression by nine copies was approximately three times
higher than from six copies. Moreover, Post et al. [14]
demonstrated that six copies had less than half the hypoxic
activity of five copies in some experiments. Therefore, the
primary purpose of our study was to assess gene activation
levels resulting from various numbers of HREs (2, 4, 6, 8,
10, and 12). In addition, in contrast to the previous studies,
which used single fixed hypoxia durations and, at most, O2
concentration of 5 or 10 %, we tested HRE gene activation
under various durations of hypoxia (6, 12, 18, and 24 h)
and hypoxic O2 concentrations (1, 2, 4, 8, and 16 % O2).
Furthermore, Post et al. [14] investigated the bidirectional
function of the HRE only as a classical enhancer element;
however, their results seemed to be erroneous based on the
wide variation in HRE background activity observed under
normoxia.
Therefore, in this study we aimed to assess the bidi-
rectional activity of multiple HREs in tandem and to
demonstrate the feasibility of SPECT imaging of tumor
hypoxia in living mice using a plasmid containing 12
tandem copies of HREs (12HRE) combined with a human
sodium/iodide symporter (NIS) reporter gene, which
encodes a membrane protein that transports (radio)iodide
and 99mTcO4
- into cells [15].
Materials and methods
Plasmid construction
A 35-bp fragment containing an HIF-1 recognition
sequence from the human VEGF gene was synthesized (50-
CCA CAG TGC ATA CGT GGG CTC CAA CAG GTC
CTC TT-30) [16]. Two copies of this fragment (2HRE)
were tandemly ligated using a 5-nucleotide linker and were
inserted up to six times into the pGL4.26 vector (Promega,
Madison, WI, USA), which contains a synthetic firefly
luciferase gene (Luc2), a minimal promoter (MinP), and a
hygromycin B phosphotransferase gene, at a HindIII site in
the multiple cloning site (MCS) in either a sense (nHRE?)
or antisense (nHRE-) orientation with respect to the Luc2
gene (Figs. 1, 2, 3).
It is difficult to directly compare the gene activation
levels obtained from different experiments, because the
Renilla luciferase activity used as a control for transfection
efficiency to normalize firefly luciferase activity varied
considerably among experiments. Thus, we also generated
vector constructs (dual-luc-nHREs) containing firefly and
Renilla luciferase reporter genes at each side of various
numbers (2, 4, 6, 8, 10, and 12) of HREs to directly
compare the bidirectional gene activation levels by multi-
ple HREs. A Renilla luciferase gene (Rluc2) excised from
pRL-TK vector (Promega) was first used to replace the
Luc2 gene in the pGL4.26 vector, and then a HindIII-
BamHI fragment from this construct containing the mini-
mal promoter and Renilla luciferase gene was cloned into
the HindIII site in the MCS of the nHRE- vectors, so that
Table 1 Previous and current reports on in vitro assessment of gene activation levels by multiple HREs under various hypoxic conditions
First author HRE origin HRE copy number Direction of HRE O2 concentration (%) Hypoxia duration (h)
Dachs [4] mPGK 3 Sense 0, 0.1, 1, 2, 5 16
Shibata [12] hVEGF 3, 5, 10 Sense 0.02, 0.2, 1, 2, 5 6
Ruan [13] hEPO 3, 6, 9 Sense 0, 0.3, 1 16
Post [14] hVEGF, hEPO 1, 2, 3, 4, 5, 6 Bidirectional 1, 3, 5, 10 48
Current study hVEGF 2, 4, 6, 8, 10, 12 Sense, antisense, bidirectional 1, 2, 4, 8, 16 6, 12, 18, 24
HRE hypoxia-responsive element, mPGK mouse phosphoglycerate kinase-1, hVEGF human vascular endothelial growth factor, hEPO human
erythropoietin
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the two sequences from each end of the repeat HRE to the
start codons of the two luciferase genes were identical
(dual-luc-nHRE, Fig. 4).
To determine whether multiple HREs can induce gene
expression in vivo in response to hypoxia, we generated a
vector construct containing 12HRE and the NIS reporter
gene (pGL4-12HRE-NIS). To construct pGL4-12HRE-
NIS, a human NIS cDNA (GenBank: NM000453) was
synthesized by polymerase chain reaction [17] and used to
replace the firefly luciferase gene in the 12HRE- vector
(Fig. 5). Sequence analysis was performed to confirm the
nucleotide sequences and the directions of the inserted
fragments in all vector constructs.
Cell culture and hypoxic conditions
Human colon carcinoma HCT116 cells (American Type
Culture Collection, Manassas, VA, USA) were cultured in
Fig. 1 Relative luciferase
activity of various numbers of
HREs under various durations
of hypoxia (1 % O2). Left HRE
in sense orientation with respect
to the Luc2 gene (nHRE?);
right HRE (nHRE-) in
antisense orientation with
respect to the Luc2 gene. A
schema of the constructs is
attached on top
Fig. 2 Relative luciferase
activity of various numbers of
HREs under various
concentrations of DFO stress.
Left HRE in sense orientation
with respect to the Luc2 gene
(nHRE?); right HRE in
antisense orientation with
respect to the Luc2 gene
(nHRE-). A schema of the
constructs is attached on top
Fig. 3 Relative luciferase activity of various numbers of HREs under
various hypoxic O2 concentrations. Left HRE in sense orientation
with respect to the Luc2 gene (nHRE?); right HRE in antisense
orientation with respect to the Luc2 gene (nHRE-). A schema of the
constructs is attached on top
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DMEM/F-12 (Life Technologies, Carlsbad, CA, USA)
supplemented with 10 % fetal bovine serum and antibiotics
(50 IU of penicillin and 50 lg/mL of streptomycin) in a
humidified tri-gas incubator (HeraCell; Thermo Scientific,
Waltham, MA, USA) at 37 C with 5 % CO2. O2 con-
centrations were electronically controlled by the incubator.
Hypoxia-like chemical stress was induced by DFO (Cal-
biochem, San Diego, CA, USA) dissolved in the culture
medium.
Luciferase assay
Twenty-four hours after seeding at 2 9 105 cells/well in
6-well plates, cells were transiently transfected using the
Lipofectamine 2000 reagent (Life Technologies) according
to the manufacturer’s protocol. The nHRE? and nHRE-
vectors were co-transfected with pRL-SV40 (Promega) as a
control vector for transfection efficiency, because in pre-
liminary experiments we found that the expression of pRL-
Fig. 4 Ratio of bidirectional
activity of various numbers of
HRE under various hypoxic
conditions. Left DFO stress;
Right hypoxic gas stress. Dotted
lines indicate the regression line
for data of 12HRE;
y = 0.0004x ? 1.06 (left),
y = 0.0125x ? 0.744 (right). A
schema of the constructs is
attached on top
Fig. 5 Results of in vitro
99mTcO4
- uptake assay (top
right) and representative in vivo
99mTcO4
- SPECT images
(bottom). In the bar graph, the
numbers indicate the mean
99mTcO4
- uptake levels, and the
error bars represent the
standard deviations. In the
bottom figure, fusion (coronal)
and SPECT (MIP) views in each
image set were made from the
same mouse. A schema of the
constructs is attached on the top
left
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SV40 was less influenced by hypoxia than pRL-TK (Pro-
mega) and pRL-CMV (Promega) were. On the other hand,
dual-luc-nHRE vectors containing both firefly and Renilla
luciferases were transfected on their own. Twelve hours
later, the culture dishes were washed in growth medium
twice and cells were exposed to hypoxic conditions (1, 2, 4,
8, and 16 % O2 or DFO 20, 40, 80, 160, and 320 lg/mL
growth medium). Immediately after hypoxic stress, cell
lysates were prepared with 250 lL of passive lysis buffer
using the Dual Luciferase Assay kit (Promega), and lucif-
erase activities were measured with a luminometer
according to the manufacturer’s protocol. The results were
expressed as the relative ratio of firefly luciferase activity
to Renilla luciferase activity for correction of transfection
efficiency in experiments using nHRE? and nHRE-, and
as the ratio of bidirectional activity in experiments using
dual-luc-nHRE. These experiments were performed in
triplicate.
Stable cell lines
The day after seeding a density of 1 9 106 cells/10 cm
dish, cells were transfected with pGL4-12HRE-NIS by the
calcium phosphate coprecipitation method (pH 7.12) as
previously described [18]. For clonal selection, cells were
cultured in the presence of 1000 lg/mL of Hygromycin B
(Life Technologies). Drug-resistant colonies were isolated
and expanded for Western blotting for NIS protein as
previously described [15]. Stable cell lines were estab-
lished by the confirmation of significant NIS protein
expression under hypoxia (1 % O2) for 12 h [19].
In vitro 99mTcO4
- uptake assay
NIS protein function was tested by an in vitro 99mTcO4-
uptake assay as previously described [19]. Briefly, 24 h
after seeding at 5 9 104 cells/well on 24-well plates, the
cells were incubated under hypoxic (1 % O2) or normoxic
(21 % O2) conditions for 12 h. Then the cells were incu-
bated in medium supplemented with 3.7 kBq/well of
99mTcO4
- for 30 min, washed gently and quickly twice
with ice-cold HBSS (Life Technologies) after the medium
was removed, and lysed with 0.5 mL of 0.1 N NaOH.
In vitro 99mTcO4
- uptake levels were measured with a
gamma-counter and represented as the percentage of
radioactivity in the cell lysates relative to the total radio-
activity added. These experiments were performed in
triplicate.
Mouse subcutaneous xenograft model
All animals were treated humanely in compliance with the
‘‘Guide for the Care and Use of Laboratory Animals’’
formulated by the US National Research Council [20], and
this study was conducted in accordance with our institu-
tional ‘‘Guide for the Care and Use of Laboratory Ani-
mals’’ (publication no. 7–35, revised in 2011). Twelve
male BALB/c nu/nu nude mice (6 weeks old, Japan SLC,
Hamamatsu, Japan) were fed the commercial diet MB-1
(Funabashi farm, Funabashi, Japan) that was not supple-
mented with iodine. Mice were injected subcutaneously
into the right flank with a cell suspension (3 9 106 cells/
100 lL PBS) of either 12HRE-NIS stably transfected or
non-transfected HCT116 cells. In vivo SPECT/computed
tomography (CT) imaging was performed approximately
3 weeks later when the xenograft diameter reached 5 mm,
because preliminary pathological examinations showed
that the xenografts often showed central cell death, prob-
ably due to spontaneous intratumoral hypoxia, when the
diameter exceeded 5 mm.
In vivo SPECT/CT imaging
In vivo SPECT imaging was performed in the mouse
subcutaneous xenograft model to visualize the NIS
expression induced by 12HRE in response to spontaneous
intratumoral hypoxia in vivo. SPECT images were
obtained for 90 min, starting at 30 min after the intrave-
nous injection of 99mTcO4
- (74 MBq) and pimonidazole
(Hypoxyprobe-1; HPI Inc., Burlington, MA, USA) at a
dose of 60 lg/g body weight, using a small-animal SPECT/
CT system FX with a single-pinhole PH10 collimator
(Gamma Medica-Ideas, Northridge, CA, USA) as descri-
bed previously [21]. CT images were acquired for ana-
tomical orientation with the same positioning as for the
SPECT imaging. Both SPECT and CT image data were
reconstructed as tomographic images without attenuation
correction, coregistered automatically, and displayed using
maker-supplied software. Fusion (coronal) view displayed
coronal sections of a color-scaled SPECT image overlaid
on a gray-scaled CT image. SPECT (MIP) view displayed a
maximum intensity projection (MIP) of SPECT image
coregistered with a 3D volume-rendering CT image of the
bone density.
Immunohistochemistry
The specimens were fixed in formalin and sliced into 4 lm
adjacent sections using a standard microtome. Paraffin
sections were immunostained with mouse monoclonal
Hypoxyprobe-1 MAb1 antibody (HPI Inc., Burlington,
MA, USA), or mouse monoclonal anti-human NIS anti-
body (clone FP5A; Lab Vision, Fremont, CA, USA) after
antigen retrieval. Then, the sections were washed in TBS,
incubated with the secondary antibody (ENVISION mouse
HRP; Dako Japan), and stained with 3,30-diaminobenzidine
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(Dako Japan) according to the manufacturer’s instructions.
Slides were counterstained with Mayer’s hematoxylin.
Statistical analysis
Linear regression analysis was used to assess correlations
between hypoxic severity and the ratio of the bidirectional
activities of multiple HREs. Two-way ANOVA and Bon-
ferroni post-tests were used to compare 99mTcO4
- uptake
in cell lines under hypoxic and normoxic conditions. All
statistical analyses were performed using Prism 6 for Mac
OS X (GraphPad Software, La Jolla, CA, USA). A p value
less than 0.05 was considered to be statistically significant.
Results
Gene activation levels by various numbers of HREs
under various durations of hypoxia
The expression of the firefly luciferase reporter gene
induced by various numbers (2, 4, 6, 8, 10, and 12) of
HREs was assessed after hypoxic stress at 1 % O2 during
four different test periods (6, 12, 18, and 24 h; Fig. 1). All
the constructs were found to induce reporter gene expres-
sion in response to hypoxia. The relative luciferase activ-
ities under various durations of hypoxia ranged from three
times to 85 times higher than those under normoxia and
tended to gradually increase with increasing HRE copy
number. The results may appear somewhat erroneous,
probably due to various small unavoidable errors in the
urgent experimental procedures, such as the volume of
culture medium in each well, the number of harvested cells
from each well, transient changes in oxygen levels of the
hypoxic chamber by opening/closing the door, and so on.
Yet, our results seem to be less erroneous compared with
previous studies [12–14].
Regarding hypoxia duration, the relative luciferase
activities of all the constructs increased remarkably during
6–12 h of hypoxia, but not beyond 12 h. This was probably
because HREs responded to hypoxia rapidly, but the syn-
thesis of luciferase took several hours.
Gene activation levels by various numbers of HREs
under various concentrations of deferoxamine mesylate
(DFO)
The gene activation levels by various numbers (0, 4, 6, 8,
10, and 12) of HREs were assessed under hypoxia-like
chemical stress using various concentrations of DFO (20,
40, 80, 160, and 320 lg/mL growth medium) dissolved in
the culture medium for 12 h. (Fig. 2). Gene activation
levels by HREs showed similar patterns of response to the
hypoxia-like chemical stress in both directions. The
expression levels of the reporter gene tended to increase
with increasing HRE copy number, but a saturation effect
was seen in constructs with more than 6 or 8 copies of
HREs. The expression levels of the reporter gene increased
with increasing DFO concentration, although data were
somewhat erroneous at 320 lg/mL of DFO concentration
because some of the cells started to die at this
concentration.
Gene activation levels by various numbers of HREs
under various O2 concentrations
The gene activation levels by various numbers (0, 4, 6, 8,
10, and 12) of HREs were also assessed under hypoxic
conditions with various O2 concentrations (1, 2, 4, 8, and
16 % O2) for 12 h (Fig. 3). The expression levels of the
reporter gene decreased with increasing O2 concentration,
but could be detected at low levels even under mild
hypoxia at 16 % O2 with high numbers of HREs. Com-
pared to the experiment using DFO, this result appeared
much erroneous at low O2 concentration (e.g., 1, 2, 4 %).
The reason is probably an indirect influence of hypoxic gas
as mentioned above.
Bidirectional gene activation levels by various numbers
of HREs under various hypoxic conditions
We measured the ratios of the bidirectional gene activation
levels from the vector constructs containing firefly and
Renilla luciferase reporter genes at each side of various
numbers (2, 4, 6, 8, 10, and 12) of HREs (dual-luc-nHREs)
under hypoxia-like chemical stress using various DFO
concentrations (20, 40, 80, 160, 320 lg/mL growth med-
ium) for 12 h and under hypoxic conditions with various
O2 concentrations (1, 2, 4, 8, and 16 % O2) for 12 h
(Fig. 4). Linear regression analyses indicate that the ratio
of the bidirectional activity of HRE was almost a constant
of 1, regardless of the hypoxic severity.
Application of a 12HRE-NIS reporter construct
for in vivo SPECT imaging of tumor hypoxia
In a preliminary in vitro 99mTcO4
- uptake assay, we con-
firmed that cells stably transfected with pGL4-12HRE-NIS
show up to 17 times higher 99mTcO4
- uptake under
hypoxia as under normoxia, whereas the non-transfected
negative control cells showed little 99mTcO4
- uptake
regardless of oxygen conditions (Fig. 5). In in vivo SPECT
imaging of mouse subcutaneous xenograft models, NIS
expression induced by 12HRE in response to spontaneous
intratumoral hypoxia was visualized as a focal 99mTcO4
-
uptake in all xenografts of 12HRE-NIS transfected cells
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(SUVmax = 1.86 ± 0.11), but in none of the non-trans-
fected negative control cells (SUVmax = 0.16 ± 0.02)
(Fig. 5). We also performed immunohistochemical staining
of the xenografts with NIS antibody and pimonidazole and
confirmed expression of NIS in accordance with staining
with pimonidazole as a conventional gold standard of tis-
sue hypoxia at the central area of the xenograft sections
(Fig. 6). No prominent central necrosis (cell death) was
observed in any sections.
Discussion
In the current study, we assessed gene activation levels by
multiple HREs under various hypoxic conditions in vitro.
The findings in this study were as follows: (1) gene acti-
vation levels tended to increase with increasing HRE copy
number, but saturation was observed in constructs with
more than 6 or 8 copies of the HRE, (2) gene activation
levels by the HRE increased remarkably during 6–12 h of
hypoxia, but not beyond 12 h, (3) gene activation levels by
the HRE decreased with increasing O2 concentrations, but
could be detected even under mild hypoxia in 16 % O2, (4)
the bidirectionally proportional activity of the HRE was
confirmed regardless of the hypoxic conditions, and (5)
NIS expression upregulated by 12HRE in response to
tumor hypoxia could be visualized in in vivo SPECT
imaging.
These findings suggest that all the constructs containing
6 or 8–12 HREs could be candidates for in vivo SPECT
imaging of genetic response to hypoxia. With regard to
bidirectional gene activation of the HRE, enhancers are
generally known to activate genes on both sides, unless an
insulator between the enhancer and its target gene impedes
the activation, but the mechanism has not been clarified
yet [22]. Our findings (Figs. 1, 2, 3) suggested there
were no big differences in the gene activation levels
between HRE? (sense orientation) and HRE- (antisense
orientation). More importantly, our results guaranteed the
proportionality of the bidirectional activity of the HRE,
regardless of hypoxic severity, for its potential application
to combinations of (1) a therapeutic gene and a reporter
gene, for monitoring gene therapy [23] and (2) two dif-
ferent reporter genes, for multimodal imaging (e.g., optical
imaging, single-photon emission computed tomography
[SPECT], positron emission tomography [PET], and mag-
netic resonance imaging [MRI]) [24, 25], or (3) two dif-
ferent therapeutic genes for synergetic effect in multimodal
therapy [26].
The reason for using the NIS radionuclide reporter gene
instead of the firefly luciferase gene in in vivo imaging was
that optical imaging is more affected by signal attenuation
and tissue scattering, and thus is less sensitive and less
quantitative in the living animal body than radionuclide
imaging [27]. Among several radionuclide reporter genes,
NIS has many advantages; various radioactive iodides
(123I, 124I, 125I, 131I) and pertechnetate (99mTcO4
-) are
available as its reporter probe depending on imaging
modalities; this avoids the troublesome problems of tracer
synthesis, labeling stability, and metabolites. For future
clinical applications of reporter gene imaging in humans,
we believe such non-toxic and non-immunogenic methods
using human-oriented genes will be essential [15].
The rationale for using 12HRE in SPECT imaging in
spite of the saturation effect seen when using more than 6
or 8 copies of HREs was that tandem repeat DNA
sequences are commonly known to be unstable and, con-
sequently, the number of repeats may decrease during
DNA replication, repair, and recombination in vivo [28,
29]. Therefore, we thought that a higher HRE copy number
would be able to induce high gene activation more stably
in vivo than 6HRE or 8HRE, even though the in vitro gene
activation levels were the same.
One of the limitations of this study was the use of only a
single cell line. Since it has been reported that the absolute
expression levels of HIF-1 are different among cancer cell
Fig. 6 Representative staining images of xenograft. Left Hematoxylin–eosin staining; center immunohistochemical staining of pimonidazole;
right immunohistochemical staining of NIS. Bars indicate 1 mm
Ann Nucl Med (2014) 28:1011–1019 1017
123
lines [30], further studies using different cell lines will be
interesting to explore the relationship between the expres-
sion of HIF-1 and gene activation by HRE. In the current
methodological study, however, we needed to compare the
gene activation levels by various numbers of HRE under
various hypoxic conditions in a constant experimental
setting with a fixed cell line. Another limitation was lack of
the measurement of HIF-1, for example, by immunohis-
tochemistry or Western blotting. However, we did not
assume that HIF-1 levels at the time of killing correlate
with gene activation levels by multiple HREs, because (1)
intratumoral blood flow and thus the HIF-1 levels must
dynamically change, and (2) the gene activation by mul-
tiple HREs is a consequence for some duration of hypoxia
with a time lag for protein synthesis [31, 32]. In addition,
the measurement of HIF-1 is technically difficult due to the
structural instability [18].
For future research into the use of multiple HREs, we
have started a research project to characterize hypoxia-
targeted radiotracers that have been used for PET imaging
in humans. There are two categories of hypoxia-targeted
PET tracers: the fluorine-radiolabeled nitroimidazole
derivatives such as [18F]fluoromisonidazole (FMISO) [33]
and the copper-radiolabeled dithiosemicarbazone com-
plexes such as 60/62Cu-diacetyl-bis(N4-methylthiosemicar-
bazone) (ATSM) [34] These PET tracers are all retained in
hypoxic cells because of their low redox potential, and the
levels of their tumor accumulation are known to be related
to the prognosis. Nevertheless, both categories of PET
tracers have been also reported to show different intratu-
moral distributions [35, 36]. To realize an effective
hypoxia-targeted intensity-modulated radiotherapy
(IMRT), the intratumoral distributions of the two catego-
ries of PET tracers representing true tumor hypoxia related
to treatment resistance need to be determined. Therefore,
we are planning to utilize the mouse subcutaneous xeno-
graft model of 12HRE-NIS for comparison of the uptake
regions of the hypoxia PET tracers with those of 99mTcO4
-
(or 124I) as the gold standard of genetic response to hypoxia
leading to therapy resistance.
In conclusion, the results of this study will help to
achieve a multilateral understanding and assessment of the
hypoxic activities of multiple HREs and will become the
basis for hypoxia-targeted imaging and therapy in the
future.
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